Posted On: 12/12/2013 3:54:38 PM
Post# of 36729
"What holds BBio from leaving SKTO and going to greener pastures? Colorado has many of companies head of SKTO up and running now!"
From what Hoye has said publicly, he's happy with SK3. Of course, we shareholders hope it stays that way. SK3 made possible their years of pioneering research and dauntless efforts come into fruition. Based on the following, SK owns 100% of the assets of BBORL, INC (Berkeley Bio-Organic Research Laboratories) including the intellectual property and knowhow of BBORL, Inc.
"On June 30, 2013, SK3 Group closed an acquisition agreement to acquire 100% of the assets of BBORL, INC (Berkeley Bio-Organic Research Laboratories), a California Corporation for 20 million shares of SK3 Group, common stock, valued at the closing market price of $0.0182 on the closing date, or a total of $364,000.
The main concentration of BBORL is consultation with many collectives in the development and production of non-psychoactive cannabinoid medicines, primarily for the treatment of cancer, allowing patients to obtain medically efficacious doses without attendant, and possibly negative, psychoactive consequences. A secondary interest is the development and production of equipment for the manufacture and production of cannabinoid-based medicines. Berkeley Bio has made substantial strides in these areas.
The principal assets acquired consisted of the intellectual property and knowhow developed by BBORL, Inc. through its former operations. BBORL, Inc. remains an independent company but provides research and development services to the Company in the medical marijuana filed on an exclusive basis."
From what Hoye has said publicly, he's happy with SK3. Of course, we shareholders hope it stays that way. SK3 made possible their years of pioneering research and dauntless efforts come into fruition. Based on the following, SK owns 100% of the assets of BBORL, INC (Berkeley Bio-Organic Research Laboratories) including the intellectual property and knowhow of BBORL, Inc.
"On June 30, 2013, SK3 Group closed an acquisition agreement to acquire 100% of the assets of BBORL, INC (Berkeley Bio-Organic Research Laboratories), a California Corporation for 20 million shares of SK3 Group, common stock, valued at the closing market price of $0.0182 on the closing date, or a total of $364,000.
The main concentration of BBORL is consultation with many collectives in the development and production of non-psychoactive cannabinoid medicines, primarily for the treatment of cancer, allowing patients to obtain medically efficacious doses without attendant, and possibly negative, psychoactive consequences. A secondary interest is the development and production of equipment for the manufacture and production of cannabinoid-based medicines. Berkeley Bio has made substantial strides in these areas.
The principal assets acquired consisted of the intellectual property and knowhow developed by BBORL, Inc. through its former operations. BBORL, Inc. remains an independent company but provides research and development services to the Company in the medical marijuana filed on an exclusive basis."
(0)
(0)
